ArticleBMC gastroenterology2025
Impact of cholecystectomy on Metabolic dysfunction-Associated Steatotic Liver Disease and metabolic syndrome: a 6-month prospective cohort study.
Article in BMC gastroenterology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Hydrogel-Based Therapeutic Strategies for Post-Cholecystectomy NAFLD: Targeting Bile Acid Signaling, Gut Microbiota, Inflammation, and Hepatic Fibrosis.Gels (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundCholecystectomy, a common surgery, may cause metabolic changes linked to bile acid metabolism. Early studies suggest a possible link between cholecystectomy and Metabolic dysfunction-Associated Steatotic Liver Disease (MASLD) and metabolic syndrome, but findings are inconclusive. This 6-month study aimed to assess how elective cholecystectomy affects metabolic syndrome development and MASLD progression in a Middle Eastern population.
methodsParticipants included 51 patients undergoing elective cholecystectomy and 49 matched controls. MASLD grade and metabolic syndrome status were assessed at baseline and six months post-intervention using ultrasonography and standard clinical criteria.
resultsA total of 100 patients were included in the present study, with 51 assigned to the cholecystectomy group and 49 to the control group. Over a six-month follow-up period, individuals in the cholecystectomy group experienced a significant decrease in body mass index (BMI) (p < 0.05) and fasting blood sugar (FBS) levels (p < 0.05). However, this group also exhibited a significant increase in systolic blood pressure (SBP) and diastolic blood pressure (DBP) (p < 0.05). In contrast, the control group showed significant improvements in FBS (p < 0.05) and HDL cholesterol levels (p < 0.05). Logistic regression analysis revealed that undergoing cholecystectomy was linked to a higher likelihood of developing metabolic syndrome (OR = 9.63, p < 0.05).
conclusionsOur findings highlight the potential metabolic implications of cholecystectomy. Cholecystectomy was associated with reduced BMI and improved fasting glucose but significantly increased blood pressure over 6 months. Highlighting the need for careful metabolic monitoring post-surgery.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.